Floatz logo

Monomethyl Fumarate

Melanoma (Skin Cancer)

Therakos LLCSmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

20 Active assets in the Melanoma (Skin Cancer) cohort.

Asset / SponsorPhaseRating
LENVATINIB
Shanghai Zhongshan Hospital
Phase 2B
TECHNETIUM, TC-99M
Vastra Gotaland Region
Phase 3B
lns8801
Linnaeus Therapeutics, Inc.
Phase 2/3CCC
VITPSO
Therakos LLC
Phase 2CCC
Pucotenlimab
Shanghai Zhongshan Hospital
Phase 2CCC

View all 20 →

Same molecule, other indications

Monomethyl Fumarate is also rated in:

Blood Stem Cell Transplant FailureDormant
BBB
Indicative ·
76 / 100
View asset →
Fanconi AnemiaDormant
BBB
Indicative ·
74 / 100
View asset →
Refractory Anemia With Excess BlastsDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →